Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: A pilot study of 36 patients

Annals of Oncology

Volumn 12, Issue 12, 2001, Pages 1749-1755

  Haioun, C ^a   Mounier, N ^b   Quesnel, B ^c   Morel, P ^d   Rieux, C ^a   Beaujean, F ^a   Marolleau, J P ^b   Belhadj, K ^a   Simon, D ^b   Gaulard, Ph ^a   Lepage, E ^a   Gisselbrecht, Ch ^b   Reyes, F ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d Centre Hospitalier de LENS   (France)

Author keywords

Autotransplant; Non Hodgkin's lymphoma; Tandem

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BLEOMYCIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MORPHINE; PREDNISONE; VINDESINE;

ADULT; ARTICLE; B CELL LYMPHOMA; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HUMAN; LEUKAPHERESIS; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; STEM CELL MOBILIZATION; TOXOPLASMOSIS; TREATMENT OUTCOME; VEIN OCCLUSION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; PILOT PROJECTS; PREDNISONE; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINDESINE;

EID: 0035698123     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013578523579     Document Type: Article

References (27)

1. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
2. Bone marrow transplantation prolongs survival after relapse in aggressive lymphoma patients treated with the LNH-84 regimen
3. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
4. VACOP-B vs. VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-Hodgkin's lymphoma cooperative study group
5. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2
6. Survival benefit of high dose therapy over sequential chemotherapy in poor risk aggressive non-Hodgkin's lymphoma. Final analysis of the prospective LNH87-2 protocol. A GELA study
7. A predictive model for aggressive non-Hodgkin's lymphoma
8. Failure of first line inductive high-dose chemotherapy in poor risk patients with aggressive lymphoma: Updated results of the randomized LNH93-3 study
9. Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD)
10. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkin's disease or non-Hodgkin's lymphoma
11. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma
12. Total therapy with tandem transplants for newly diagnosed multiple myeloma
13. Single vs. double transplantation in myeloma: A prospective randomized trial of the inter groupe francophone du myélome (IFM)
14. Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer
15. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: No improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, carboplatin
16. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma
17. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginian, November 1997
18. Reporting results of cancer treatment
19. Non parametric estimation from incomplete observations
20. Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation
21. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications
22. T-cell depleted autologous bone marrow transplantation therapy: Analysis of immune deficiency and late complications
23. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myéloma
24. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma. A multicenter phase II study
25. Phase II study of Rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
26. Investigation of monoclonal antibody therapy with conventional and high-dose treatment: Current clinical trials